December 18, 2015
December 18, 2015 - PRESSADVANTAGE -
Invokana lawsuit intermediary ProLegal offers people who have experienced complications while taking the type 2 diabetes drug Invokana (canagliflozin) free legal consultation and advises them to find out if they qualify for financial compensation.
Attorneys have started filing lawsuits for patients who developed ketoacidosis while taking Invokana. Ketoacidosis is a serious condition in which the body produces high levels of blood acids called ketones. The U.S. Food and Drug Administration (FDA) has identified 20 cases of ketoacidosis in patients treated with Invokana or the same type of drug, all these patients required emergency room visits or hospitalization.
In 2013, FDA approved Invokana to improve glycemic control in adults with type 2 diabetes. Invokana was the first diabetes treatment approved in a new class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. Invokana and other SGLT2 inhibitors prevent glucose from being reabsorbed into the blood. Instead, glucose is secreted by kidneys and it leaves the body in urine. This elevates the risk of urinary tract infections, which may develop into life-threatening blood infections and kidney infections. On December 4, the FDA ordered the manufacturers of SGLT2 inhibitors to add warnings of risks for ketoacidosis and urinary tract infections to the drugs’ labels. The FDA now advises (http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm) patients to stop taking their SGLT2 inhibitor and seek medical attention immediately if they have any symptoms of ketoacidosis, including nausea, vomiting, abdominal pain, tiredness, and trouble breathing.
In May, 2015, the FDA issued a warning letter (http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm) about canagliflozin (Invokana and Invokamet). According to the warning, these Type 2 diabetes medications may lead to diabetic ketoacidosis. If left untreated, this condition can be deadly. Recently, the FDA also issued a safety alert warning that the canagliflozin (Invokana, Invokamet) is related to the increased risk of bone fractures, and added new information about decreased bone mineral density. Patients who developed ketoacidosis or urinary tract infections after taking Invokana or Invokamet have started to file lawsuits claiming the drugs' manufacturers Johnson & Johnson and its subsidiary Janssen Pharmaceuticals failed to warn about the risks of the drugs.
###
For more information about ProLegal Injury, contact the company here:
ProLegal Injury
James Hill
415-671-6163
4557 Vineyard Drive
Madison, OH 45041
ProLegal Injury will match you with a Law Firm that will provide a Free Case Review to Claimants who may have suffered complications due to harmful prescription drugs, medical devices or toxic products.
James Hill
4557 Vineyard Drive
Madison, OH 45041
415-671-6163
